Medarex to collaborate with GenPat77 on human antibody therapeutics

By E. Janene Geiss

Philadelphia, Aug. 22 - Medarex, Inc. and GenPat77 Pharmacogenetics AG have entered into a collaborative agreement to develop fully human therapeutic antibody products.

The companies said they plan to use Medarex's UltiMAb Human Antibody Development System to generate antibodies to novel disease targets provided by GenPat77, according to a company news release.

Under the agreement, Medarex and GenPat77 said they plan to share product development and commercialization responsibilities on any antibody products resulting from this collaboration.

Other financial terms of the agreement were not disclosed.

"We are pleased to have the opportunity to combine our fully human antibody technology with GenPat77's novel targets and to work together toward the development of potential new therapeutics for autoimmune diseases," Donald L. Drakeman, president and chief executive officer of Medarex, said in the release.

GenPat 77 is a Berlin-based privately held biopharmaceutical company focused on the development of immune modulatory products.

Medarex is a Princeton, N.J., biopharmaceutical company focused cancer, inflammation, autoimmune disorders and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.